Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of $462.85 million. The enterprise value is $332.64 million.

Market Cap	462.85M
Enterprise Value	332.64M

Important Dates

The next confirmed earnings date is Tuesday, May 13, 2025, before market open.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Altimmune has 77.01 million shares outstanding. The number of shares has increased by 33.35% in one year.

Current Share Class	77.01M
Shares Outstanding	77.01M
Shares Change (YoY)	+33.35%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	0.88%
Owned by Institutions (%)	53.06%
Float	76.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23,142.60
Forward PS	n/a
PB Ratio	3.27
P/TBV Ratio	3.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	16,632.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.11, with a Debt / Equity ratio of 0.01.

Current Ratio	13.11
Quick Ratio	12.90
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-11,463.56

Financial Efficiency

Return on equity (ROE) is -59.86% and return on invested capital (ROIC) is -40.31%.

Return on Equity (ROE)	-59.86%
Return on Assets (ROA)	-36.85%
Return on Invested Capital (ROIC)	-40.31%
Return on Capital Employed (ROCE)	-80.08%
Revenue Per Employee	$339
Profits Per Employee	-$1.61M
Employee Count	59
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.76% in the last 52 weeks. The beta is 1.11, so Altimmune's price volatility has been higher than the market average.

Beta (5Y)	1.11
52-Week Price Change	-16.76%
50-Day Moving Average	5.20
200-Day Moving Average	6.62
Relative Strength Index (RSI)	61.84
Average Volume (20 Days)	2,134,115

Short Selling Information

The latest short interest is 22.58 million, so 29.32% of the outstanding shares have been sold short.

Short Interest	22.58M
Short Previous Month	22.44M
Short % of Shares Out	29.32%
Short % of Float	29.58%
Short Ratio (days to cover)	10.37

Income Statement

In the last 12 months, Altimmune had revenue of $20,000 and -$95.06 million in losses. Loss per share was -$1.34.

Revenue	20,000
Gross Profit	-82.21M
Operating Income	-103.17M
Pretax Income	-101.35M
Net Income	-95.06M
EBITDA	-102.93M
EBIT	-103.17M
Loss Per Share	-$1.34

Full Income Statement

Balance Sheet

The company has $131.89 million in cash and $1.68 million in debt, giving a net cash position of $130.21 million or $1.69 per share.

Cash & Cash Equivalents	131.89M
Total Debt	1.68M
Net Cash	130.21M
Net Cash Per Share	$1.69
Equity (Book Value)	123.51M
Book Value Per Share	1.71
Working Capital	126.79M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-79.85M
Capital Expenditures	n/a
Free Cash Flow	-79.85M
FCF Per Share	-$1.04

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-515,860.00%
Pretax Margin	-475,295.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-33.35%
Shareholder Yield	-33.35%
Earnings Yield	-20.54%
FCF Yield	-17.25%

Dividend Details

Analyst Forecast

The average price target for Altimmune is $21.00, which is 249.42% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$21.00
Price Target Difference	249.42%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	636.44%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altimmune has an Altman Z-Score of 12.93 and a Piotroski F-Score of 1.

Altman Z-Score	12.93
Piotroski F-Score	1